X4 Pharmaceuticals, Inc. Common Stock (XFOR)
X4 Pharmaceuticals, Inc. (XFOR) is a biopharmaceutical company focused on developing therapies for rare diseases, particularly immune-mediated and hematologic disorders. The company's approach involves targeting mechanisms of immune regulation to address unmet medical needs in underserved patient populations.
Company News
X4 Pharmaceuticals announced a public offering of 45,860,000 shares and pre-funded warrants, expecting to raise approximately $135 million to fund Phase 3 development of mavorixafor for chronic neutropenic disorders.
A more selective small-cap index has consistently outperformed the Russell 2000
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. bluebird bio shares rose 6.6% to $3.05 on Monday. Here are some other stoc...
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Insiders are buying these penny stocks but are they worth the risk? The post Penny Stocks To Buy: 6 Insider Picks Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.